TY - JOUR
AU1 - Sanchez-Avila, Ronald
AU2 - Merayo-Lloves, Jesus
AU3 - Riestra, Ana
AU4 - Fernandez-Vega Cueto, Luis
AU5 - Anitua, Eduardo
AU6 - Begoña, Leire
AU7 - Muruzabal, Francisco
AU8 - Orive, Gorka
AB - Int Ophthalmol (2018) 38:1193–1204 https://doi.org/10.1007/s10792-017-0582-7 ORIGINAL PAPER Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops . . . Ronald Mauricio Sanchez-Avila Jesus Merayo-Lloves Ana Cristina Riestra . . . Luis Fernandez-Vega Cueto Eduardo Anitua Leire Begona Francisco Muruzabal Gorka Orive Received: 26 August 2016 / Accepted: 5 June 2017 / Published online: 15 June 2017 Springer Science+Business Media B.V. 2017 Abstract and Visual Analogue Scale (VAS) were also evaluated Purpose To provide preliminary data about efficacy before and after treatment with PRGF. The influence and safety of plasma rich in growth factors (PRGF) of some patients’ clinical variables on results was eye-drops in neurotrophic keratitis (NK) and to assessed. Safety assessment was also performed analyze the possible influence of certain variables on reporting all adverse events. treatment outcomes. Results Thirty-eight treated eyes in a total of thirty- Methods This retrospective study included patients one patients were evaluated, of which five cases had no with stages 2–3 of NK treated with PRGF eye-drops. prior response to autologous serum treatment. Most Primary endpoint was the resolution time of corneal cases (97.4%) achieved the complete resolution of ulcer defect. Outcome measures including 
TI - Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops
JF - International Ophthalmology
DO - 10.1007/s10792-017-0582-7
DA - 2017-06-15
UR - https://www.deepdyve.com/lp/springer-journals/treatment-of-patients-with-neurotrophic-keratitis-stages-2-and-3-with-LKs1ZU4Fpz
SP - 1193
EP - 1204
VL - 38
IS - 3
DP - DeepDyve
ER -